Kestra Medical Technologies, Ltd.’s (NASDAQ:KMTS) Lock-Up Period To End on September 2nd

Kestra Medical Technologies’ (NASDAQ:KMTS) lock-up period is set to expire on Tuesday, September 2nd. Kestra Medical Technologies had issued 11,882,352 shares in its IPO on March 6th. The total size of the offering was $201,999,984 based on an initial share price of $17.00. After the expiration of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Analyst Ratings Changes

Separately, Wells Fargo & Company cut their price target on shares of Kestra Medical Technologies from $28.00 to $27.00 and set an “overweight” rating for the company in a report on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $27.33.

Kestra Medical Technologies Stock Performance

Shares of Kestra Medical Technologies stock opened at $17.72 on Tuesday. The company has a 50 day moving average of $16.05. The company has a current ratio of 6.72, a quick ratio of 6.72 and a debt-to-equity ratio of 0.20. Kestra Medical Technologies has a fifty-two week low of $13.25 and a fifty-two week high of $26.15.

Hedge Funds Weigh In On Kestra Medical Technologies

Large investors have recently bought and sold shares of the company. Yu Fan bought a new stake in shares of Kestra Medical Technologies during the first quarter worth about $56,880,000. T. Rowe Price Investment Management Inc. acquired a new position in Kestra Medical Technologies in the 1st quarter valued at approximately $56,613,000. Omega Fund Management LLC acquired a new position in Kestra Medical Technologies in the 1st quarter valued at approximately $44,754,000. Alliancebernstein L.P. lifted its holdings in shares of Kestra Medical Technologies by 10.8% during the second quarter. Alliancebernstein L.P. now owns 1,312,085 shares of the company’s stock worth $21,754,000 after purchasing an additional 128,312 shares during the period. Finally, Eventide Asset Management LLC grew its stake in shares of Kestra Medical Technologies by 285.7% in the second quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock worth $17,584,000 after purchasing an additional 785,557 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.